Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

Inclusion Criteria: * Subjects with residual (uncontrolled) hypertension on lisinopril monotherapy, defined as 24-hour ambulatory diastolic BP \>85 mmHg. Exclusion Criteria: A subject meeting any of the following conditions will be excluded from the study: * History of serious adverse effects with ACE inhibitor, Coreg, or valsartan * Known or suspected causes of secondary hypertension (e.g., renovascular stenosis, primary hyperaldosteronism) * Known ischemic heart disease requiring beta-blocker therapy (includes angina, prior transmural myocardial infarction, coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty or stenting within 6 months prior to study entry). * Heart failure (NYHA Functional Class II-IV) * Obstructive valvular heart disease or obstructive hypertrophic cardiomyopathy * Presence of clinically significant ventricular or supraventricular arrhythmias (e.g. atrial fibrillation/flutter), pre-excitation syndrome, second or third degree AV block, other conduction defects necessitating the implantation of a permanent cardiac pacemaker, or sick sinus syndrome. * Chronic kidney disease (serum creatinine \>2.5 within past 6 months) * Uncontrolled diabetes mellitus (i.e., a fasting blood glucose \>200 mg/dL \[\>11.1 mmol/L\] or hemoglobin A1c \> 10% * History of alcohol or other drug abuse within 6 months prior to enrollment * Concomitant treatment or probable need for treatment with prohibited medications. NSAIDs, diabetes medications and other chronic meds are permitted if continued throughout study without dosage change. * Any other medical condition which renders the subject unable to complete the study or which would interfere with optimal participation in the study or produce a significant risk to the subject * Those with persistent systolic BP elevations above 179 mmHg will be discontinued from the study as will those with any significant adverse effect of medication. * Positive pregnancy test or failure to practice adequate contraception in women of child-bearing potential * Bronchospastic asthma requiring chronic steroid or inhaler therapy * Any women with child-bearing potential